Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation

Leukemia

Volumn 13, Issue 9, 1999, Pages 1383-1389

  Eder, M ^a   Battmer, K ^a   Kafert, S ^a   Stucki, A ^a   Ganser, A ^a   Hertenstein, B ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chronic myeloid leukemia; Minimal residual disease; Real time RT PCR; Stem cell transplantation

Indexed keywords

BCR ABL PROTEIN; BUSULFAN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; THIOTEPA;

ARTICLE; BONE MARROW TRANSPLANTATION; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMPUTER PROGRAM; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE TRANSFUSION; PATIENT MONITORING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX CHROMOSOME;

EID: 0032845686     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401489     Document Type: Article

References (22)

1. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. New Engl J Med 1988; 319: 990-998.
2. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Heinze B, Georgii A, v Wussow P, Bartram C, Grieammer M, Bergmann L, Essers U, Fakge C, Hochhaus A, Queir U, Sick C, Meyer P, Schmitz N, Verpoort K, Eimermacher H, Walther F, Westerhausen M, Kleeberg UR, Heilein A, Käbisch A, Barz C, Zimmermann R, Meuret G, Tichelli A, Berdel WE, Kanz L, Anger B, Tigges FJ, Schmid L, Brockhaus W, Zankovich R, Schläfer U, Weinfels I, Mainzer K, Tobler A, Perker M, Hohnloser J, Messener D, Thiele J, Buhr T, Anasari H, and the German CML Study Group. Randomized comparison of busulfan and hydoxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 1993; 82: 398-407.
3. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
4. The Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon a-2b for chronic myeloid leukemia. Blood 1998; 91: 2713-2721.
5. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J. Interferon alpha 2b (IFN) combined with cytarabine versus interferon alone in chronic myelogenous leukemia. New Engl J Med 1997; 337: 223-229.
6. McGlave PB, de Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, Simonsson B, Carella A, Aeppli D. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343: 1486-1488.
7. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan KM, Anasetti C. Bone marrow transplants from unrelated donors for patients with chronic myelogenous leukemia in chronic phase. New Engl J Med 1998; 338: 962-968.
8. Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM, Heimpel H, Hochhaus A, Klein JP, Kolb HJ, McGlave PB, Passweg JR, Rowlings PA, Sobocinski KA, Horowitz MM, and the German CML Study Group. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood 1998; 91: 1810-1819.
9. Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, Bourquelot P, Greinix H, Frickhofen N, Ringden O, Zander A, Apperley JF, Gorin C, Borkett K, Schwab G, Goebel M, Russel NH, Gratwohl A. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995-1003.
10. Kolb HJ, Schattenberg A, Goldmann JM, Hertenstein B, Jacobson N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermüller J, de Witte T, Holler E, Ansari H. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
11. Lion TH, Izraeli S, Henn T, Gaiger A, Mor W, Gadner H. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia 1992; 6: 495-499.
12. Lin F, van Rhee F, Goldman JM, Cross NCP. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996; 87: 4473-4478.
13. Holland P, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA 1991; 88: 7276-7280.
14. Lee LG, Connell CR, Bloch W. Allelic discrimination by nick-translation PCR with fluorogenic probes. Nucleic Acids Res 1993; 21: 3761-3766.
15. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6: 986-994.
16. Lie YS, Petropoulos CJ. Advances in quantitative PCR technology: 5′ nuclease assays. Curr Opin Biotechnol 1998; 9: 43-48.
17. Maurer J, Janssen JWG, Thiel E, van Denderen J, Ludwig WD, Aydemir U, Heinze B, Fonatsch C, Harbott J, Reiter A, Riehm H, Hoelzer D, Bartram CR. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 1991; 337: 1055-1058.
18. Baurmann H, Nagel S, Binder T, Neubauer A, Siegert W, Huhn D. Kinetics of graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Blood 1998; 92: 3582-3590.
19. Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A, de Witte T. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102: 768-774.
20. Savonet V, Maenhaut C, Miot F, Pirson I. Pitfalls in the use of several housekeeping genes as standards for quantitation of mRNA: the example of thyroid cells. Anal Biochem 1997; 247: 165-167.
21. Kafert S, Krauter J, Ganser A, Eder M. Differential quantitation of alternatively spliced messenger RNAs using isoform-specific real-time RT-PCR. Anal Biochem 1999; 269: 210-213.
22. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldmann JM, Cross NCP. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-a therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549-1555.